Despite a revenue increase to $563,000 in 2026Q1, the company continues to struggle with a negative operating margin of -6.2% due to heavy R&D spending.
| Sales/Revenue | 1.49M | 1.12M | 43K | 0 | 0 | 0 | 0 | 0 |
| Revenue Growth % | 520.42% | 2511.63% | - | - | - | - | - | - |
| Cost of Goods Sold | 317K | 327K | 0 | 0 | 0 | 0 | 0 | 0 |
| COGS % of Revenue | - | 29.12% | - | - | - | - | - | - |
| Gross Profit | 1.17M | 796K | 43K | 0 | 0 | 0 | 0 | 0 |
| Gross Margin % | 78.71% | 70.88% | 100% | - | - | - | - | - |
| Gross Profit Growth % | - | 1751.16% | - | - | - | - | - | - |
| Operating Expenses | 14.04M | 13.31M | 11.01M | 11.4M | 9.95M | 5.67M | 3.2M | 3.9M |
| OpEx % of Revenue | - | 1184.86% | 25611.63% | - | - | - | - | - |
| Selling, General & Admin | 8.2M | 7.04M | 4.99M | 5.73M | 5.65M | 2.63M | 818K | 899K |
| SG&A % of Revenue | - | 626.63% | 11600% | - | - | - | - | - |
| Research & Development | 5.84M | 6.27M | 6.03M | 5.67M | 4.3M | 3.04M | 2.39M | 3M |
| R&D % of Revenue | - | 558.24% | 14011.63% | - | - | - | - | - |
| Other Operating Expenses | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Operating Income | -12.87M | -12.51M | -10.97M | -11.4M | -9.95M | -5.67M | -3.2M | -3.9M |
| Operating Margin % | -864.34% | -1113.98% | -25511.63% | - | - | - | - | - |
| Operating Income Growth % | - | -14.04% | 3.74% | -14.53% | -75.45% | -77% | 17.76% | - |
| EBITDA | -12.87M | -12.51M | -10.97M | -11.39M | -9.94M | -5.66M | 0 | -3.84M |
| EBITDA Margin % | -864.27% | -1113.98% | -25511.63% | - | - | - | - | - |
| EBITDA Growth % | -43.45% | -14.04% | 3.69% | -14.54% | -75.63% | - | 100% | - |
| D&A (Non-Cash Add-back) | 1K | 0 | 0 | 6K | 6K | 9K | 3.2M | 0 |
| EBIT | -12.87M | -12.51M | -10.97M | -11.4M | -9.95M | -5.49M | -3.2M | -3.84M |
| Net Interest Income | 366K | 427K | 384K | -108K | 0 | -834K | -587K | 63K |
| Interest Income | 366K | 427K | 384K | 0 | 57K | 0 | 3K | 63K |
| Interest Expense | 0 | 0 | 0 | 108K | 57K | 834K | 590K | 0 |
| Other Income/Expense | 600K | 1.34M | 2.16M | 1.16M | 61K | -653K | -594K | 57K |
| Pretax Income | -12.27M | -11.17M | -8.81M | -10.23M | -9.89M | -6.32M | -3.8M | -3.84M |
| Pretax Margin % | -824.04% | -994.48% | -20497.67% | - | - | - | - | - |
| Income Tax | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Effective Tax Rate % | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% |
| Net Income | -12.27M | -11.17M | -8.81M | -10.23M | -9.89M | -6.32M | -3.8M | -3.84M |
| Net Margin % | -823.98% | -994.48% | -20497.67% | - | - | - | - | - |
| Net Income Growth % | -20.78% | -26.71% | 13.86% | -3.47% | -56.37% | -66.51% | 1.07% | - |
| Net Income (Continuing) | -12.27M | -11.17M | -8.81M | -10.23M | -9.89M | -6.32M | -3.8M | -3.84M |
| Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EPS (Diluted) | -0.32 | -0.32 | -0.37 | -0.50 | -0.54 | -0.40 | -0.25 | -0.22 |
| EPS Growth % | 17.26% | 13.51% | 26% | 7.41% | -35% | -60% | -13.64% | - |
| EPS (Basic) | - | -0.32 | -0.37 | -0.50 | -0.54 | -0.40 | -0.25 | -0.22 |
| Diluted Shares Outstanding | 38.03M | 35.33M | 23.61M | 20.58M | 18.1M | 17.87M | 17.32M | 17.32M |
| Basic Shares Outstanding | 38.03M | 35.33M | 23.61M | 20.58M | 18.1M | 17.87M | 17.32M | 17.32M |
| Dividend Payout Ratio | - | - | - | - | - | - | - | - |
Binary clinical trial outcome
As reported in recent financial filings, RNXT recorded $563,000 in revenue for 2026Q1, representing a significant sequential increase from prior periods, yet this growth remains entirely tied to non-recurring clinical trial collaborations rather than a scalable commercial product launch or sustainable market demand for its technology.
The revenue trajectory is currently erratic and reflects milestone-based activity rather than consistent operational growth. Investors should interpret these figures as a byproduct of research funding rather than an indicator of future commercial success, as the company has yet to establish a repeatable sales model.
Based on the company's income statement, R&D expenses remain the primary driver of the cost structure, consistently consuming over $1.2 million per quarter as the firm funds the TIGeR-PaC trial, which appears to be the sole focus of current capital allocation and operational activity.
The high concentration of spending in R&D highlights the company's status as a pre-commercial entity with limited expense flexibility. Management's discipline is currently tested by the necessity of maintaining these high burn rates to reach critical clinical milestones, leaving little room for operational efficiency improvements.
According to the latest quarterly data, RNXT maintains a deeply negative operating margin of -6.2%, which, while improved from previous quarters, underscores the company's inability to scale operating income against its fixed cost base while remaining in the high-intensity phase of clinical development.
The lack of positive operating leverage is expected for a clinical-stage biotech, but the persistent gap between revenue and operating expenses suggests that the company is far from achieving self-sustaining operations. Any delay in the clinical trial timeline may further exacerbate this leverage profile by extending the period of cash consumption.
As indicated by the company's reported cash position of approximately $7 million, the current burn rate suggests a high probability of near-term equity dilution, which may significantly impact shareholder value if the company fails to reach its next clinical data readout before capital is fully exhausted.
Short-term liquidity constraints represent a material risk that could force management into unfavorable financing terms. Investors should monitor the cash-to-burn ratio closely, as the current financial trajectory appears to prioritize trial completion over balance sheet preservation, potentially leading to further equity dilution.
Quick answers to the most common questions about buying RNXT stock.
For fiscal year 2025, RenovoRx, Inc. (RNXT) reported total revenue of $1.1M.
RenovoRx, Inc. (RNXT) reported a net loss of $11.2M for the fiscal year ending 2025.
RenovoRx, Inc. (RNXT) reported an operating income of $-12.5M, resulting in an operating profit margin of -1114.0%. This margin reflects the operational efficiency of the business before interest and taxes.
RenovoRx, Inc. (RNXT) generated $0.8M in gross profit for the year, representing a gross profit margin of 70.9%. This demonstrates the company's core pricing power and production efficiency.